Managing the transition: switching bioanalytical laboratories during a clinical trial – a sponsor’s perspective

Bioanalytical (BA) data are foundational to clinical trial integrity and regulatory success. Yet, circumstances such as regulatory noncompliance, operational disruptions, resource limitations, or evolving analytical needs can necessitate a BA laboratory transition during a clinical trial. Through the lens of a real-world case study and supported by broader industry experience, this manuscript explores the operational, scientific, and regulatory challenges of BA laboratory transitions. We examine four potential scenarios that trigger such changes, the risks to data continuity and compliance, and the significant implications for sponsors. The manuscript outlines actionable, multidisciplinary strategies for managing transitions: from vendor qualification and project planning to Corrective and Preventive Action (CAPA) implementation, method transfer, and ongoing performance assessment. When guided by early risk recognition, transparent communication, and organizational learning, laboratory transitions though challenging, can be successfully navigated to protect trial outcomes and strengthen the resilience of clinical programs.

1. Introduction

Clinical trials evaluate the safety and efficacy of new drug therapies, diagnostics, and medical devices in humans. Across the spectrum of drug development spanning Phase I, II, III, and IV trials, each stage represents a point where a drug’s progression is assessed [1]. At the core of these trials is the generation and interpretation of Bioanalytical (BA) data, which are indispensable for evaluating pharmacokinetic (PK), pharmacodynamic (PD), biomarker, and immunogenicity assessments [2–4]. BA data underpin dose selection, safety evaluation and regulatory submissions. The reliability and integrity of BA data are fundamental for credible clinical trial outcomes, supporting regulatory submissions and treatment guidance [5]. Global regulatory frameworks (International Council for Harmonisation (ICH M10), U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA)) shape expectations for validation, data integrity, and inspection readiness in bioanalysis [6–8].

Clinical trials frequently span multiple geographies and these studies involve collecting and analyzing large numbers of biological samples, which are processed at qualified BA laboratories. BA Contract Research Organizations (CRO) develop and validate BA methods, process large sample volumes and ensure compliance for the drug approval [9]. When selecting a CRO for early method development, it is critical to consider many factors. Key selection factors include scientific capability, modality expertise, capacity (lead time), past performance (if applicable), data turnaround timelines, throughput, regulatory adherence, sustained study support, and potential partnership [10]. Despite careful planning, unforeseen circumstances can necessitate BA method transition away from a CRO posing substantial risks to data deliveries and creating logistical hurdles in sample and method transfer [11].

Acknowledging the practical risks, we present a real-world case study, analyze common transition scenarios, and outline management practices to successfully navigate such transitions.